Evidence map›Paper›PMID 37955079›Full record

ArticleCancer biomarkers : section A of Disease markers2023

Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with fibrosis.

Julie B Siegel, Patrick Nasarre, Lillian Hsu, Rupak Mukherjee, Meghan Gormley, Bailey Richardson, Imran Khan, Jordan E Morningstar, Eleanor Hilliard, John P O'Bryan and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Julie B SiegelDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Patrick NasarreDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Lillian HsuDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Rupak MukherjeeDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Meghan GormleyDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Bailey RichardsonDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Imran KhanDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Jordan E MorningstarDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC, USA.
Eleanor HilliardDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
John P O'BryanDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Kristi L HelkeDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC, USA.
Laura SpruillDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA.
Nathan G DolloffDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Nancy Klauber-DeMoreDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
MUSC Hollings Cancer Center · USMedical University of South Carolina · USRalph H. Johnson VA Medical Center · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
Probing RAS-mediated Signaling with Monobody InhibitorsR01CA212608 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHOHEI KOIDE, John P O'Bryan · 2017 to 2026
$5.8M
Inhibitors of Oxidative Protein Folding For The Treatment of CancerR01CA245081 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DOLLOFF, NATHAN G. · 2020 to 2024
$2.4M
BLRD VA I01 BX002095NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA212608NCI NIH HHS R01 CA245081
6 · The paper itself

Abstract

Pancreatic adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year survival rates of 9%. We hypothesized that secreted frizzled-related protein 2 (SFRP2) may influence stromal growth in pancreatic cancer, since it increases fibrosis and collagen production in non-neoplastic pathologies. We assessed SFRP2 value as a biomarker and assessed its function in PDAC. SFRP2 gene expression in patients with PDAC was analyzed using TCGA data. Disease free survival (DFS) was analyzed using Kaplan Meier test. The effect of KRAS inhibition on SFRP2 expression in PDAC cells was assessed. The associations of stromal content with SFPR2 mRNA and protein with fibrosis were analyzed. The role of SFRP2 in mesenchymal transformation was assessed by western blot in fibroblasts. Of all cancers in TCGA, SFRP2 levels were highest in PDAC, and higher in PDAC than normal tissues (n= 234, p= 0.0003). High SFRP2 levels correlated with decreased DFS (p= 0.0097). KRAS inhibition reduced SFRP2 levels. Spearman correlation was 0.81 between stromal RNA and SFRP2 in human PDAC, and 0.75 between fibrosis and SFRP2 levels in PDAC tumors. SFRP2-treated fibroblasts displayed mesenchymal characteristics. SFRP2 is prognostic for PDAC survival, regulated by KRAS, and associated with PDAC fibrosis.

Indexed as

AdenocarcinomaPancreatic NeoplasmsHumansPrognosisProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins p21(ras)cancer biomarkersfibroblastKRASpancreasSFRP2

Identifiers

PMID37955079
PMCPMC10977449
OpenAlexW4388452694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.